- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma, 2024
- Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2024
- In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT, 2024
- Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases, 2024
- Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG), 2024
- Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study, 2024
- Transcriptome analysis of beta-catenin-related genes in CD34+ haematopoietic stem and progenitor cells from patients with AML, 2024
- A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma, 2024
- Current Landscape of iPSC Haplobanks, 2024
- A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma, 2024
- Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)., 2024
- Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis, 2024
- Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment, 2024
- In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide, 2024
- Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison, 2024
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2024
- Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells, 2024
- Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients, 2024
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group, 2023
- Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation, 2023
- Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT, 2023
- Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center, 2023
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network, 2023
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2023
- Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome, 2023
- Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study, 2023
- HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma, 2023
- An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT, 2023
- A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset, 2023
- Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data, 2023
- Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT, 2023
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial, 2023
- Werner helicase is required for proliferation and DNA damage repair in multiple myeloma, 2022
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2022
- First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey, 2022
- ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma, 2022
- Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper, 2022
- Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?, 2022
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma, 2022
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA, 2022
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial, 2022
- Manual Versus Automated Volume Reduction of Cord Blood, 2022
- Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT, 2022
- Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT, 2022
- Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis, 2022
- The efficacy and safety of second allogeneic hematopoietic stem cell transplantation., 2022
- Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia, 2022
- Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies, 2022
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, 2022
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2022
- Health\u2010related quality of life in patients with\n <scp>light chain<\/scp>\n amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009±\u2009daratumumab: Results from the\n <scp>ANDROMEDA<\/scp>\n study, 2022
- Extramedullary disease in multiple myeloma: a systematic literature review, 2022
- Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019, 2022
- Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease, 2022
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2022
- A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors, 2021
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2021
- Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, 2021
- Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications, 2021
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2021
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study, 2021
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, 2021
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2021
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, 2021
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network, 2021
- Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma, 2021
- Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group, 2021
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide\u2010pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2021
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2021
- Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review, 2021
- Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial, 2021
- Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party, 2021
- Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, 2021
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT, 2021
- Prognostic impact of early\u2010versus\u2010late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT, 2021
- HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA, 2021
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2021
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021
- Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma, 2021
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021
- CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors, 2021
- Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, 2020
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome., 2020
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT, 2020
- Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience., 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Efficacy and safety of weekly carfilzomib (70 mg/m sup2/sup ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies/title, 2020
- Efficacy and safety of weekly carfilzomib (70\u2009mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies, 2020
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM), 2020
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data, 2020
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Drug Targeting of Genomic Instability in Multiple Myeloma, 2020
- Isatuximab for the treatment of relapsed/refractory multiple myeloma, 2020
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2020
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial, 2020
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study, 2020
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2020
- Prognostic scoring system after transplantation in myeloma: predicting early relapse, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma, 2020
- Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma, 2020
- Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation, 2020
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020
- Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS), 2020
- Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT, 2020
- Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma, 2020
- Our Treatment Approach to Hairy Cell Leukemia, 2020
- Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells, 2019
- A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma, 2019
- PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma, 2019
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2019
- Insights on Multiple Myeloma Treatment Strategies, 2019
- Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies, 2019
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial, 2019
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial, 2019
- A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis, 2019
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, 2019
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, 2019
- Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens, 2019
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019, 2019
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2019
- Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma, 2019
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- The outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4T cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect, 2018
- The impact of 17 B estradiol level variations on blood lymphocyte counts among healthy females, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- title Daratumumab plus bortezomib and dexamethasone iversus/i bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR/title, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation, 2018
- Kronik Lenfositik Lösemi’de Tanı Anında Hipogammaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerine Etklili Midir?, 2018
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients., 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipientss?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- The safety of bortezomib for the treatment of multiple myeloma, 2018
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network, 2018
- Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Total Blood Lymphocyte Count Alteration During and after Pregnancy, 2017
- Subsequent malignancies after allogeneic hematopoietic stem cell transplantation, 2017
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment, 2017
- Extracorporeal photochemotherapy in mycosis fungoides, 2017
- Heparin enhances CD34 content of stem cells collected following G-CSF /- chemotherapy, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and ipost-hoc/i analyses on progression-free survival and tumour growth/title, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia., 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Large unstained cell percentage as a predictor ofefficacious peripheral stem cell mobilization in autologousstem cell transplantation, 2017
- Evaluating peritransplant albumin decline as a predictor ofacute graft versus host disease, 2017
- Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely?, 2017
- P529HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients, 2017
- A Biosimiliar G-CSF filgrastim is as effective as a referencedrug however itis not as cost effectiveas it supposed to beand by the way no impact on the health care system, 2017
- Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience, 2017
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study, 2017
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial, 2017
- THE IMPACT OF 17Β ESTRADIOL LEVEL VARIATIONS ON BLOOD LYMPHOCYTE COUNTS AMONG HEALTHY FEMALES, 2017
- extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease, 2017
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, 2016
- Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4., 2016
- Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial)., 2016
- Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study., 2016
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants, 2016
- How to Improve Cord Blood Engraftment, 2016
- Editorial How to Improve Cord Blood Transplantation By Enhancing Cell Counts or Engraftment, 2016
- Flow Cytometrıc Aldehyde Dehydrogenase Aldh Assay Enables A Fast And Accurate Human Umblical Cord Blood Hematopoietic Stem Cell Assessment, 2016
- Phase 2 study of tabalumab a human anti B cell activating factor antibody with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2016
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone the PANORAMA 1 trial a randomised placebo controlled phase 3 trial, 2016
- HLA polymorphism and risk of multiple myeloma, 2016
- Daratumumab Bortezomib and Dexamethasone for Multiple Myeloma, 2016
- Central nervous system involvement by multiple myeloma A multi institutional retrospective study of 172 patients in daily clinical practice, 2016
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma outcomes by prior treatment, 2016
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation, 2015
- Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups, 2015
- Effects of in utero cord blood collection on post-cesarean hemoglobin levels, 2015
- Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival, 2015
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, 2015
- Insight into human protease activated receptor-1 as anticancer target by molecular modelling, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, 2015
- Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma, 2015
- Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial, 2015
- Antilymphocyte Thymocyte Globulin for the Treatment of Steroid Refractory Acute Graft Versus Host Disease 20 Year Experience at a Single Center, 2015
- Analysis of Final Data from the Multinational Non Interventional Observational Emmos Study NCT01241396 in Patients Pts with Multiple Myeloma MM in Real World Clinical Practice, 2015
- Retrospective matched pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2015
- Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values, 2014
- Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation, 2014
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, 2014
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial, 2014
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study, 2014
- Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial, 2014
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, 2014
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2014
- HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma a multicentre randomised double blind phase 3 trial, 2014
- Hemorrhagic Cystitis as a Complication of Bone Marrow Transplantation, 2013
- Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma, 2013
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study, 2013
- Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease, 2013
- Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma, 2012
- Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients, 2012
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study., 2012
- IMWG consensus on maintenance therapy in multiple myeloma, 2012
- Management of treatment-emergent peripheral neuropathy in multiple myeloma, 2012
- Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells, 2012
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials, 2012
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma, 2012
- Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective, 2011
- Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up, 2011
- Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial, 2011
- An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells, 2011
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement, 2011
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, 2011
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN), 2011
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials, 2011
- The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans, 2011
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3, 2011
- Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic?, 2011
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective, 2010
- Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial, 2010
- Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations, 2010
- Lack of Prognostic Value of CD34 in Adult AML, 2009
- Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF, 2009
- Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival, 2009
- International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma, 2009
- Vitiligo after Hematopoietic Cell Transplantation: Six Cases and Review of the Literature, 2008
- Familial Multiple Myeloma Associated with Disorders of Chronic Inflammation: First Report from Turkey, 2008
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group, 2008
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, 2008
- High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis, 2007
- International uniform response criteria for multiple myeloma, 2006
- Expression of IFITM1 in chronic myeloid leukemia patients, 2005
- Filgrastim-Mobilized Peripheral Blood Progenitor Cells Versus Bone Marrow Transplantation For Treating Leukemia: 3-Year Results From The EBMT Randomized Trial, 2005
- HLA A B C DR haplotypes linkeage and frequencies observed inAnkara University Turkey a report from Tran, 2005
- Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease, 2004
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow, 2003
- Differences between graft product and donor side effects following bone marrow or stem cell donation, 2003
- CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914), 2001
- The effect of G-CSF on lymphocyte subsets and CD34 cells in allogeneic stem cell transplantation, 2001
- Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM), 2001
- Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation, 2001
- CD41 and CD42 hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia, 2001
- Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF, 2000
- Thrombopoietic Cytokines in Patients with Iron Deficiency Anemia with or without Thrombocytosis, 2000
- Chronic graft-versus-host disease complicated by membranous glomerulonephritis, 1999
- The impact of the CD34 cell dose on engraftment in allogeneic peripheral blood stem cell transplantation, 1999
- Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey, 1998
- Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia, 1998
- HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia, 1997
- Hepatitis B virus infection in allogeneic bone marrow transplantation, 1997
- A RAPID DRUG SENSITIVITY ASSAY FOR NEOPLASMATIC CELLS, 1988
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide, 2024
- External Valıdatıon Of Three Exıstıng Early Myeloma Relapse Scores (By Ebmt, Cıbmtr, And Gımema) In A Sıngle Center Shows Major Dıfferences, 2023
- Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study, 2024
- ASCO EDUCATIONAL BOOK, ISBN: EDBK_349643, 2022
- İmmünohematolojide Güncel Başlıklar, ISBN: 9786059160582, 2021
- Hematopoetik Kök Hücre Nakli Kitabı, ISBN: 9786058469914, 2019
- Türkiye Klinikleri Hematoloji Özel Dergisi, ISBN: 978-605-7505, 2018
- Türkiye Klinikleri Hematoloji Özel Dergisi, ISBN: 978-605-7505, 2018
- Hematolog, ISBN: 2146-6408, 2017
- Hematolog, ISBN: 2146-6408, 2017
- Hematolog, ISBN: 2146-6408, 2017
- İmmünoloji, ISBN: 978-605-89294-2-5, 2017
- İmmünoloji, ISBN: 978-605-89294-2-5, 2017
- Bone Marrow and Stem Cell Transplantation, ISBN: eISBN-10:1-59745-223-8, 2007
- Bone Marrow and Stem Cell Transplantation, ISBN: , 2014
